Skip to main content

Table 2 Subgroup analysis of the impact of anti-tumor therapy on death and severe disease of cancer patients with COVID-19

From: The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants

Anti-tumor therapy Solid tumour Haematological malignancy
death severe COVID-19 death severe COVID-19
OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P
Chemotherapy 1.17 (1.03–1.34) 0.0158 1.16 (0.81–1.66) 0.4072 1.41 (0.74–2.68) 0.2964 NA NA
Radiotherapy NA NA NA NA NA NA NA NA
Targeted therapy NA NA NA NA NA NA NA NA
Surgery NA NA NA NA NA NA NA NA
Endocrine therapy NA NA NA NA NA NA NA NA
Immunotherapy 0.91 (0.47–1.76) 0.7705 NA NA NA NA NA NA
Antitumor therapy 1.15 (0.94–1.42) 0.1815 1.08 (0.88–1.32) 0.4643 1.26 (0.91–1.75) 0.1597 NA NA
  1. Abbreviations NA Not available, OR Odds ratio, CI Confidence interval